 | The introduction of SCENESSE in vitiligo treatment. |
 | Dr Philippe Wolgen, Clinuvel's CEO, discusses the results of the company’s Phase III study of SCENESSE® in erythropoietic protoporphyria (CUV017) |
 | Continuing and persistent burning pain, isolation and a lack of understanding from peers has a long term impact on patients diagnosed with erythropoietic protoporphyria (EPP).
Translated Videos DE IW |
 | Non-Executive Director, Jack Wood, discusses his experiences with Good Manufacturing Practise in the pharmaceutical industry. |
 | Non-Executive Director, Jack Wood, discusses his experiences with Good Manufacturing Practise in the pharmaceutical industry. |
 | Dr Roger Aston was asked for his views on the recent announcements regarding Clinuvels new approved trade name Senesse and Senesse's listing as a treatment for EPP in Italy, .Listen to pocast... |
 | Raising children with Erythropoietic Protoporphyria (EPP) is a traumatising experience, one which few parents are able to express or understand. Watch video...
Translated Videos DE IW |
 | Erythropoietic protoporphyria (EPP) is a rare and severe UV/light related skin disorder. Watch video... |
 | Adrian was diagnosed with the genetic disease Erythropoietic Protoporphyria (EPP) when he was 5. Exposure to light causes him excruciating pain. Watch video... Translated Videos DE IW |
 | Afamelanotide holds promise as a preventative treatment, improving quality of life for patients with advanced stage bile duct cancer, undergoing Photodynamic Therapy (PDT). Watch video... |
 | Clinuvel's non-executive director Jack Wood discusses commercialization strategies. Watch video... |
 | Clinuvel directors discuss the progress of Clinuvel's clinical program with afamelanotide. Watch video... |
 | Clinuvel's CSO, Dr Hank Agersborg, discusses the company's regulatory strategy following the announcement of a confirmatory Phase III EPP study. Listen to podcast... |
 | Dr Hank Agersborg, discusses drug development at Clinuvel |
 | Clinuvel's CSO, Dr Hank Agersborg, on the final year of drug filing. Listen to podcast... |
 | Senior management in regulatory and clinical research discuss the development of afamelanotide. Watch video... |
 | In Australia, we understand, appreciate and respect light and UV. Watch video... |